U.S. Markets closed

Free Research Report as Thermo Fisher Scientific’s Quarterly Revenue Surged 23%; Adjusted EPS Jumped 20%

Stock Monitor: Fluidigm Post Earnings Reporting

LONDON, UK / ACCESSWIRE / May 11, 2018 / If you want access to our free earnings report on Thermo Fisher Scientific Inc. (NYSE: TMO), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=TMO. Thermo Fisher Scientific reported its first quarter fiscal 2018 operating and financial results on April 25, 2018. The maker of scientific instrument and laboratory supplies outperformed top- and bottom-line expectations. Additionally, the Company raised its revenue and earnings guidance for FY18. Register today and get access to over 1,000 Free Research Reports by joining our site below:


Active-Investors.com is currently working on the research report for Fluidigm Corporation (NASDAQ: FLDM), which also belongs to the Healthcare sector as the Company Thermo Fisher Scientific. Do not miss out and become a member today for free to access this upcoming report at:


Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Thermo Fisher Scientific most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:


Earnings Highlights and Summary

Thermo Fisher's revenue grew 23% to $5.85 billion for the first quarter 2018 versus $4.77 billion in Q1 2017. The Company's organic revenue growth was 7% for the reported quarter, acquisitions increased revenue by 12%, and currency translation increased revenue by 4%. Thermo Fisher's reported numbers topped analysts' estimates of $5.63 billion.

During Q1 2018, Thermo Fisher's GAAP operating income grew to $0.79 billion compared to $0.62 billion in Q1 2017. The Company's GAAP operating margin increased to 13.4% compared to 13.0% in the prior year's same quarter. For Q1 2018, Thermo Fisher's adjusted operating income grew 20% to $1.29 billion on a y-o-y basis. The Company's adjusted operating margin was 22.0% compared to 22.5% in the prior year's same quarter.

Thermo Fisher's GAAP net income was $579 million, or $1.43 per diluted share, in Q1 2018 compared to $551 million, or $1.40 per diluted share, in Q1 2017. The Company's adjusted earnings increased 20% to $2.50 versus $2.08 in the prior year's comparable quarter. Thermo Fisher's earnings beat Wall Street's estimates of $2.42 per share.

Thermo Fisher Scientific's Segment Results

During Q1 2018, the Life Sciences Solutions segment's revenue grew 10% to $1.50 billion compared to revenue of $1.36 billion in Q1 2017. The segment's adjusted operating margin increased to 34.5% versus 31.8% in the prior year's same quarter.

For Q1 2018, the Fisher's Analytical Instruments segment's revenue increased 19% to $1.26 billion compared with revenue of $1.05 billion in Q1 2017. The segment's adjusted operating margin increased to 19.6% versus 18.2% in the year earlier same quarter.

The Specialty Diagnostics segment's revenue grew 9% to $0.95 billion in Q1 2018 compared to revenue of $0.87 billion in Q1 2017. The segment's adjusted operating margin was 25.6% versus 26.9% in the year ago corresponding period.

The Laboratory Products and Services segment's results reflect the acquisition of Patheon in late August 2017. In Q1 2018, the segment's revenue surged 42% to $2.41 billion compared to revenue of $1.70 billion in Q1 2017. The segment adjusted operating margin was 11.6% versus 12.7% in the year ago same period.

Cash Matters

Thermo Fisher's cash flow from continuing operations through Q1 2018 was $80 million, and free cash flow was negative $40 million after deducting net capital expenditures of $120 million. The Company ended the reported quarter with $950 million in cash and investments. Thermo Fisher's total debt at the end of Q1 2018 was $20.9 billion, down $75 million sequentially, and the Company's leverage ratio at the end of the quarter was 3.8x total debt to adjusted EBITDA.


For full year 2018, Thermo Fisher raised its revenue guidance to a range of $23.62 billion to $23.86 billion versus its previous guidance of $23.42 billion to $23.72 billion. This would result in 13% to 14% revenue growth on a y-o-y basis. The Company raised its adjusted earnings forecast to a band of $10.80 to $10.96 versus its previous guidance of $10.68 to $10.88, reflecting for 14% to 15% growth on a y-o-y basis.

Stock Performance Snapshot

May 10, 2018 - At Thursday's closing bell, Thermo Fisher Scientific's stock advanced 2.46%, ending the trading session at $213.82.

Volume traded for the day: 1.27 million shares.

Stock performance in the last month – up 0.48%; previous three-month period – up 7.59%; past twelve-month period – up 25.06%; and year-to-date – up 12.61%

After yesterday's close, Thermo Fisher Scientific's market cap was at $86.13 billion.

Price to Earnings (P/E) ratio was at 34.80.

The stock has a dividend yield of 0.32%.

The stock is part of the Healthcare sector, categorized under the Medical Laboratories & Research industry. This sector was up 0.9% at the end of the session.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors